Bioavailability and pharmacokinetics of a new, slow-release potassium chloride capsule

✍ Scribed by J. Arnold; J. T. Jacob; B. Riley

• Publisher: John Wiley and Sons
• Year: 1980
• Tongue: English
• Weight: 363 KB
• Volume: 69
• Category: Article
• ISSN: 0022-3549
• DOI: 10.1002/jps.2600691217

✦ Synopsis

The bioavailability of a new, slow-release potassium chloride product consisting of coated beads in a hard gelatin capsule was compared with the bioavailahility of two marketed products, an elixir and a slowrelease tablet, by determining the urinary excretion of potassium. Twelve healthy male volunteers were dosed with a total of 80 mEq of potassium, in a single dose for the capsule and tablet and in three 26.6-mEq doses at 6-hr intervals for the elixir. Mean recoveries in 24-hr urine potassium levels from all three dosage forms after subtracting normal urine potassium excretion levels were 50.8% from the capsule, 53.9% from the elixir, and 63.1% from the tablet. Maximum excretion rates were reached a t 2.0 hr for the elixir, 6.8 hr for the capsule, and 4.0 hr for the tablet. Fewer side effects were reported with the capsule than with the elixir and tablet.

Keyphrases Potassium chloride-bioavailability and pharmacokinetics of slow-release capsule Bioavailability-potassium chloride in slow-release capsule 0 Pharmacokinetics-potassium chloride in slowrelease capsule Excretion rate (mEq/hr) = [urine potassium (mEq)mean control urine potassium (mEq) for urine collection periodllurine collection period (hr).